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assess the factors inﬂuencing annual treatment costs. Logistic
regression analysis was conducted to assess the association
between obesity and related clinical factors. RESULTS: A total of
341 (3.4%) children or adolescents received an obesity diagnosis
during the study period. The average annual treatment costs were
$7481 (SD  8371) for patients experiencing obesity and $5364
(SD  15,322) otherwise. A total of 4204 (42.5%) patients
received atypical antipsychotics, 2237 (22.6%) with lithium, and
5890 (59.5%) with other anticonvulsants. Being obesity is asso-
ciated with atypical antipsychotic use (odds ratio [OR] = 1.49,
95% conﬁdence interval [CI] 1.18–1.88), and key comorbidities
like diabetes mellitus (OR = 3.40, 95%CI 1.96–5.89) and hyper-
tension (OR = 4.41, 95%CI 2.70–7.20). Higher treatment cost is
associated with the use of atypical antipsychotics (p < 0.0001),
hospitalization (p < 0.0001), ER visit (p < 0.0001), and some key
comorbidities like diabetes mellitus (p < 0.0001) and substance
abuse disorder (p < 0.0001). CONCLUSION: Higher treatment
costs are associated with obesity in children or adolescents with
bipolar disorder. Metabolic complications should be considered
by clinical practitioners when prescribing medication in this
population.
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Health Insurance Review & Assessment Services, Seoul, South Korea
Organization: Health Insurance Review & Assessment Services
(HIRA), Seoul, Korea.
Problem or Issue Addressed: Policy makers of Korean govern-
ment decided to increase the rate of public expenditure on health
per total expenditure on health (coverage rate) in the patients
with cancer. There had been conﬂicts between health care pro-
viders and decision makers of health insurance in the use of
off-label anticancer drug.
Goals: (1)Stepwise increase coverage rate of the patients with
cancer; (2)Rational control of off-label drug use related to treat-
ment of cancer including chemotherapeutic drugs and drugs for
cancer pain; (3)To control the reimbursement for the patients
with cancer in the limited budget allocation.
Outcomes items used in the decision: Safety and effectiveness
data from the literature and cost of drug.
Implementation Strategy: A Project to enhance coverage rate of
treatment of cancer started in September, 2005. The project
consists of the registry of the patients with cancer, and the special
committee for review of drugs related to treatment of cancer. The
handouts for the meetings have been made according to the
‘evidence based review manual’ which had been made by evi-
dence based health care team of HIRA. It is systematic approach
to retrieve information related to the safety and effectiveness
about the drugs. The rate of the patient’s payment per beneﬁt
schedule is reduced from 20% to 10%.
Results: The total number of patients whose medical fees were
claimed by health care provider was 42.8 million in 2005 and it
was 43.4 million in 2006 increased by 1.4%. The total number of
patients with cancer among them was 670 thousands in 2005
and it was 710 thousands in 2006, increased by 6.0%. The rate
of public expenditure on health per total expenditure on health in
the patients with cancer increased from 49.6% to 71.0%. The
rate of patients taken with anticancer chemotherapy increased
from 5.9% to 7.9%. The expected allocated budget was 597
million $ and the actual spending money was 524 million $. The
conﬂicts about off-label drug use have decreased.
Lessons Learned: The project was performed successfully by
evidence based decision making process and reasonable use of off
label drug use.
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Problem or Issue Addressed: The Pharmacy Cost Management
Committee of the Partners Healthcare System (PHS), a consor-
tium of seven greater Boston area hospitals, has recognized the
need to control the future growth rate of pharmaceuticals by
managing the utilization of new, high cost pharmaceutical tech-
nologies and learning from best practices across the network and
country. The Center for Drug Policy (CDP) was established in
August 2007 to provide the analytical resources to support the
Pharmacy Directors and multidisciplinary teams of physician and
pharmacist content experts in this endeavor.
Goals: The major objectives of the CDP are to forecast and
manage the introduction of new, high cost pharmaceutical tech-
nologies and to streamline the development and implementation
of common guidelines across the network. Additional objectives
of the CDP are to 1) identify and coordinate cost savings oppor-
tunities, 2) conduct prospective utilization reviews and assess-
ment, 3) share best practices across the network, and 4)
benchmark against high performance organizations nationwide.
Outcomes items used in the decision: Both process and outcome-
related measures will be measured. For process-related measures,
the number of the following outputs and select intermediate
steps will be assessed quarterly: guidelines (drug/therapeutic
class/disease), budget-impact models, guideline dissemination
and implementation, and assessment of guideline impact.
Outcome-related measures will be assessed at a global level and
a project-speciﬁc level. At the global level, annual drug pur-
chases, drug cost/case-mix adjusted discharge, and drug cost/
case-mix adjusted patient day will be measured quarterly at each
hospital. At a project-speciﬁc level, outcomes will depend on the
pharmaceutical technology but would include clinical (e.g.,
adherence to guidelines, time to event, complications, etc.) and
economic measures (e.g., volume of drug, length of stay, drug
purchases, etc.)
Implementation Strategy: To establish the CDP, the CDP leader-
ship met with key stakeholders across the network of hospitals,
undertook a targeted literature review of cost management strat-
egies in the hospital setting, and conducted an on-site visit to
another hospital’s CDP. Access to and training on key data
resources including drug purchasing data, computerized physi-
cian order entry, and cost accounting systems was obtained. A
database to track emerging drug therapies and tools to assist in
project management were created. Internal processes and tools
were developed to ensure quality, consistency, and documenta-
tion of guideline development. To facilitate sharing best practices
across the hospital network, presentation opportunities have
been provided at monthly CDP meetings; in addition, a monthly
memo summarizing key Pharmacy & Therapeutics Committees
activities across the network has been prepared and distributed
to Pharmacy leadership. Templates for ongoing internal report-
ing were also developed.
Results: As the CDP was established in August 2007, data col-
lection is ongoing; an overview of anticipated results is, however,
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